OncoMatch/Clinical Trials/NCT05842707
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
Is NCT05842707 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies dualCAR-NK19/70 cell for refractory or relapsed b-cell non-hodgkin lymphoma.
Treatment: dualCAR-NK19/70 cell — To find the highest tolerable dose of dualCAR-NK19/70 (a type of cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 overexpression (CD19+)
Previously confirmed diagnosis as CD19+ or CD70+ B-NHL
Required: CD70 overexpression (CD70+)
Previously confirmed diagnosis as CD19+ or CD70+ B-NHL
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: immunotherapy or chemotherapy
Relapsed or Refractory DLBCL and tFL after 2 lines Immunotherapy or chemotherapy
Must have received: immunotherapy or chemotherapy
disease progression after more than 4 courses of standard Immunotherapy or chemotherapy
Must have received: autologous hematopoietic stem cell transplantation
disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation (auto-HSCT)
Must have received: immune chemotherapy
Relapsed or Refractory MCL must be 1 line with immune chemotherapy
Must have received: BTK inhibitor
BTK inhibitors are resistant or intolerant as 2-line therapy
Must have received: chemotherapy including rituximab and anthracycline (rituximab, anthracycline)
Relapsed or Refractory disease after chemotherapy including rituximab and anthracycline
Must have received: CAR-T cell therapy
Either having failed or Relapsed after CAR-T therapy at 3 months of assessment
Lab requirements
Blood counts
ANC > 1000/μL, Platelet count > 45,000/μL, Hemoglobin > 80g/L
Kidney function
creatinine clearance > 60 mL/min; glomerular filtration rate > 50 ml/min
Liver function
ALT/AST ≤2.5x ULN for age; total bilirubin and alkaline phosphatase ≤1.5x ULN for age
Cardiac function
ejection fraction (EF) ≥ 45% by ECHO or MUGA
Adequate reserve of organ function: (A) Serum ALT/AST ≤2.5x ULN for age; (B) creatinine clearance > 60mL/min; (C) total bilirubin and alkaline phosphatase ≤1.5x ULN for age; (D) glomerular filtration rate > 50 ml/min; (E) Cardiac ejection fraction (EF) ≥ 45% as determined by an echocardiogram (ECHO) or Multigated Radionuclide Angiography (MUGA); (F) Baseline oxygen saturation >92% on room air; (G) Absolute neutrophil count > 1000/μL, Platelet count > 45,000/μL, Hemoglobin > 80g/L
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify